Source: Media Outreach
HONG KONG SAR – Media OutReach – 11 May 2021 – Researchers from Hong Kong Baptist University (HKBU), in collaboration with Cornell University, have developed a novel targeted therapy for triple-negative breast cancer (TNBC) that uses a specially-designed nano-carrier to deliver the Chinese medicine compound gambogic acid (GA). The invention enhances the anti-cancer effect of GA and reduces its damage to off-target organs. The invention has the potential to become a more effective therapeutic option for TNBC.
A research team led by Professor Bian Zhaoxiang (left) and Dr Kwan Hiu-yee (right) of HKBU’s School of Chinese Medicine collaborates with Cornell University to develop a nano-carrier that increases treatment efficacy of gambogic acid for TNBC.
The study was supported by the Vincent and Lily Woo Foundation, and the research findings have been published in the international medical journal Frontiers in Oncology.
GA as a breast cancer treatment and its limitations
TNBC accounts for 10-24% of all breast cancer cases and it also grows and spreads faster than other types of breast cancer. There are limited treatment options for TNBC and it has a high risk of recurrence and metastasis. In the advanced stage of the disease, the five-year relative survival rate is only about 12%.
GA is a herbal compound isolated from a dry, brownish resin called gamboge, which is derived from Garcinia hanburyi, a plant with a long history of medicinal use in Southeast Asia. Previous studies have shown that GA can inhibit the growth of cancer cells. However, its clinical application is limited by the fact that it is rapidly eliminated from the circulation system and has poor water solubility, which makes it difficult for GA to reach the cancer cells. Furthermore, high dosages of GA can cause damage to off-target organs due to its toxicity.
Nano-carrier increases treatment efficacy of GA
In the search for a more effective treatment protocol for TNBC when compared to existing options, Professor Bian Zhaoxiang, Director and Tsang Shiu Tim Endowed Professor in Chinese Medicine Clinical Studies of the Clinical Division of HKBU’s School of Chinese Medicine (SCM) and Dr Kwan Hiu-yee, Assistant Professor of the Teaching and Research Division of SCM, together with the research team of Professor Chu Chih-Chang at Cornell University, designed a novel nano-carrier to enhance GA’s efficacy as a TNBC treatment and reduce its off-target toxicity.
The researchers made a bio-degradable nano-carrier out of polyester urea urethane (PEUU), and they decorated it with folate (also known as vitamin B9) and arginine (an amino acid). Folate receptors are highly expressed in TNBC cells, and they can serve as a target for therapy. Arginine is a positively charged amino acid, and it can attract the nano-carrier to the negatively charged tumour surface. These features enable the nano-carrier to target and deliver GA effectively to TNBC cells.
Treatment efficacy tested in mice
The research team tested the efficacy of the GA-loaded nano-carrier as a TNBC treatment in a series of mouse experiments. Two groups of mice with TNBC were treated with the same dosage of GA, one in the form of the GA-loaded nano-carrier, and the other in the form of free GA. After 17 days of treatment, the average reduction in tumour weight of the GA-loaded nano-carrier group was 67.6% higher than the free GA group. The results showed that the GA-loaded nano-carrier is more effective at shrinking the tumours than the free GA.
In addition, the group treated with the GA-loaded nano-carrier had 0.23 μg/mL of GA in their tumours two hours after injection, and the tumour GA concentration of the GA-loaded nano-carrier group was three times of the free GA group, showing that GA is being delivered to TNBC cells more effectively with the nano-carrier. Also, the concentration of GA in the plasma of the GA-loaded nano-carrier group two hour after injection was nearly three times of the free GA group, showing that the GA carried by the nano-carrier stays in the circulation system for longer.
Reduced off-target damage to other organs
Furthermore, when compared with free GA, the GA delivered by the nano-carrier caused less damage to the off-target organs of the mice including their hearts, livers and lungs. It also caused minimal damage to their kidneys and spleens as relatively low levels of GA were detected in these two organs.
“As demonstrated in our study, the novel nano-carrier for GA offers many benefits when it comes to treating TNBC,” said Dr Kwan Hiu-yee.
“The application of nanotechnology in this study modernises the delivery of Chinese medicine, thereby enhancing its therapeutic efficacy. We believe that our nano-carriers have great clinical potential to treat TNBC and other types of cancer,” said Professor Bian Zhaoxiang.
– Published and distributed with permission of Media-Outreach.com.